Pulmonary Fibrosis: Clinical Trials

410 completed, 114 unknown, 109 recruiting, 68 terminated. 203 Phase 2, 129 Not applicable, 128 Phase 1, 78 Phase 3, 24 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	203	Completed 96, Terminated 28, Recruiting 26, Active not recruiting 15, Unknown 15, Withdrawn 12, Not yet recruiting 8, Enrolling by invitation 2, Suspended 1
Not applicable	129	Completed 65, Unknown 27, Recruiting 20, Terminated 7, Not yet recruiting 5, Active not recruiting 4, Enrolling by invitation 1
Phase 1	128	Completed 90, Recruiting 9, Terminated 9, Unknown 9, Not yet recruiting 6, Active not recruiting 3, Suspended 1, Withdrawn 1
Phase 3	78	Completed 37, Terminated 16, Recruiting 10, Unknown 7, Active not recruiting 4, Not yet recruiting 3, Enrolling by invitation 1
Phase 4	24	Completed 11, Unknown 7, Not yet recruiting 2, Terminated 2, Withdrawn 2
Early Phase 1	13	Unknown 4, Completed 3, Active not recruiting 2, Recruiting 2, Not yet recruiting 1, Terminated 1

Follow Pulmonary Fibrosis: new trials by email Literature Review of Pulmonary Fibrosis trials Research Report on Pulmonary Fibrosis

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis BMS-986278 - Pulmonary Fibrosis	Phase 3	Not yet recruiting	Bristol-Myers Squibb	2380	2026-12-16	2026-10-30
Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis Therapeutic Plasma Exchange, Rituximab, Intravenous immunoglobulin - Idiopathic Pulmonary Fibrosis	Phase 2	Not yet recruiting	University of Alabama at Birmingham	52	2026-12-01	2026-10-20
A Trial of AGMB-447 in Participants With Idiopathic Pulmonary Fibrosis AGMB-447, Placebo - Idiopathic Pulmonary Fibrosis (IPF)	Phase 2	Not yet recruiting	Agomab Spain S.L.U.	120	2026-11-30	2026-10-07
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Doses of Inhaled CHF10073 in Participants With Idiopathic Pulmonary Fibrosis CHF10073 low dose, CHF10073 high dose, Placebo - Idiopathic Pulmonary Fibrosis	Phase 1	Not yet recruiting	Chiesi Farmaceutici S.p.A.	18	2026-11-01	2026-10-21
Combined Growth Differentiation Factor-15 (GDF-15) and Lung Ultrasound for ILD Screening in Rheumatoid Arthritis and Systemic Sclerosis Lung ultrasound, GDF-15 level (ELISA), CT scan - Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc)		Not yet recruiting	Assiut University	110	2026-10-15	2026-09-25
Diaphragmatic Release vs Inspiratory Muscle Training in Pulmonary Fibrosis Diaphragmatic Release Technique (DRT), Targeted Inspiratory Muscle Training (IMT) - Pulmonary Fibrosis	Not applicable	Not yet recruiting	Pharos University in Alexandria	40	2026-10-10	2026-09-09
Gabapentin vs. Benzonatate vs. Standard of Care for Cough in ILD Gabapentin, Benzonatate 200 mg, Standard of care treatment for ILD - Interstitial Lung Disease	Phase 4	Not yet recruiting	Post Graduate Institute of Medical Education and Research, Chandigarh	177	2026-10-07	2026-10-08
Study of ORJ-001 for the Treatment of IPF ORJ-001, Placebo - Idiopathic Pulmonary Fibrosis	Phase 2	Recruiting	Oorja Bio, Inc.	95	2026-10-01	2026-10-15
Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote Monitoring Spirometer, Oximeter, Scale - Fibrotic Interstitial Lung Disease, IPF and PPF	Not applicable	Recruiting	University of California, San Francisco	200	2026-10-01	2026-10-09
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets NAL ER, Placebo - Idiopathic Pulmonary Fibrosis	Phase 3	Recruiting	Trevi Therapeutics	201	2026-09-30	2026-10-09
Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis Metformin, Matching Placebo - Idiopathic Pulmonary Fibrosis	Phase 3	Not yet recruiting	University of Massachusetts, Worcester	800	2026-09-28	2026-09-08
Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF) INS018_055 tablets, Placebo - Idiopathic Pulmonary Fibrosis	Phase 3	Recruiting	InSilico Medicine Hong Kong Limited	320	2026-09-09	2026-10-13
New Diagnostic Approaches in the Management of Inflammatory Lung Diseases Integrated Precision Medicine Platform - Chronic Obstructive Pulmonary Disease (COPD), Idiopathic Pulmonary Fibrosis	Not applicable	Not yet recruiting	Fondazione Don Carlo Gnocchi ETS	200	2026-09-01	2026-07-23
Blood Cell Count Derived Inflammatory Indexes in Acute Exacerbation of Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis		Not yet recruiting	Assiut University	70	2026-09-01	2026-08-24
A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis AK3280, Placebo, Pirfenidone - Idiopathic Pulmonary Fibrosis (IPF)	Phase 3	Not yet recruiting	Shanghai Ark Biopharmaceutical Co., Ltd.	263	2026-08-31	2026-07-22
Evaluating the Efficacy and Safety of of HSK50042 in People With Idiopathic Pulmonary Fibrosis HSK50042 dose 1, HSK50042 dose 2, HSK50042 dose 3 - Idiopathic Pulmonary Fibrosis (IPF)	Phase 2	Not yet recruiting	Haisco Pharmaceutical Group Co., Ltd.	175	2026-08-25	2026-07-27
Predictors of Pulmonary Embolism in Interstitial Lung Disease With Worsening Symptoms Pulmonary Embolism, Interstitial Lung Disease		Not yet recruiting	Assiut University	70	2026-08-01	2026-07-27
FAPI PET Imaging - An Exploratory Study [18F]FAPI-74 PET/CT - Thyroid Pathology, Head and Neck Cancer (H&N)	Phase 1 / Phase 2	Not yet recruiting	Martin Huellner	770	2026-08-01	2026-07-15
Dose-Escalation Study of Artesunate Patients With IPF Artesuante, Placebo capsules - Idiopathic Pulmonary Fibrosis	Phase 1	Recruiting	Joseph C. Wu	15	2026-08-01	2026-08-11
Emotional and Social Experiences of Antifibrotic (AF) Therapy Among Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis (PPF) Patients: A Real-World Study Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis		Completed	Boehringer Ingelheim	122	2026-08-01	2026-10-13

Showing 20 of 821. Sign in to see all of them.

Narrower conditions

Idiopathic Pulmonary Fibrosis (569)  ·  Lung Diseases, Interstitial (166)  ·  Pulmonary Disease, Chronic Obstructive (52)  ·  Lung Diseases (41)  ·  Fibrosis (34)  ·  Hypertension, Pulmonary (29)  ·  Idiopathic Interstitial Pneumonias (27)  ·  Sarcoidosis (26)  ·  COVID-19 (22)  ·  Asthma (17)  ·  Cough (17)  ·  Scleroderma, Systemic (17)  ·  Motor Activity (16)  ·  Alveolitis, Extrinsic Allergic (15)

Broader conditions

Respiratory Tract Diseases (809)  ·  Lung Diseases (780)  ·  Lung Diseases, Interstitial (655)  ·  Pathological Conditions, Signs and Symptoms (403)  ·  Pathologic Processes (377)  ·  Fibrosis (312)  ·  Disease Attributes (73)  ·  Immune System Diseases (73)  ·  Chronic Disease (64)  ·  Lung Diseases, Obstructive (62)  ·  Hypersensitivity (54)  ·  Skin and Connective Tissue Diseases (54)  ·  Hemic and Lymphatic Diseases (44)  ·  Respiration Disorders (44)

Interventions

pirfenidone (52)  ·  nintedanib (43)  ·  Blood Specimen Collection (10)  ·  Sildenafil Citrate (9)  ·  Exercise (8)  ·  Oxygen (7)  ·  Bosentan (6)  ·  Rituximab (6)  ·  Standard of Care (6)  ·  treprostinil (6)  ·  Acetylcysteine (5)  ·  BI 1015550 (5)  ·  Cyclophosphamide (5)  ·  Nalbuphine (5)  ·  pamrevlumab (5)

Sponsors

Boehringer Ingelheim (44)  ·  Hoffmann-La Roche (16)  ·  National Heart, Lung, and Blood Institute (NHLBI) (13)  ·  Royal Brompton & Harefield NHS Foundation Trust (13)  ·  Bristol-Myers Squibb (11)  ·  Assistance Publique - Hôpitaux de Paris (10)  ·  Duke University (8)  ·  National Jewish Health (8)  ·  Actelion (7)  ·  Genentech, Inc. (7)  ·  GlaxoSmithKline (7)  ·  Sunshine Lake Pharma Co., Ltd. (7)  ·  University of California, San Francisco (7)  ·  University of Pittsburgh (7)  ·  Assiut University (6)

Countries

United States (311)  ·  United Kingdom (122)  ·  France (96)  ·  China (90)  ·  Italy (89)  ·  Germany (87)  ·  Canada (85)  ·  Australia (78)  ·  Spain (70)  ·  Netherlands (55)  ·  South Korea (55)  ·  Belgium (51)  ·  Turkey (Türkiye) (42)  ·  Greece (37)  ·  Argentina (36)

Top investigators

Ganesh Raghu, MD (7)  ·  Imre Noth, MD (5)  ·  Fernando Martinez, MD (4)  ·  Jeff Swigris, DO, MS (4)  ·  Joel Moss, M.D. (4)  ·  Kevin F Gibson, MD (4)  ·  Rajan Saggar, MD (4)  ·  Sydney Montesi, MD (4)

Results publications

PMID 35688625, PMID 28388260, PMID 37391667, PMID 33902584, PMID 26835133, PMID 31047956, PMID 33434107, PMID 25890798, PMID 26111071, PMID 26968970, PMID 27708114, PMID 30072107, PMID 30116539, PMID 30472023, PMID 31153107, PMID 31401786, PMID 31914963, PMID 21571362, PMID 24177001, PMID 24834811, PMID 24836310, PMID 25770676, PMID 26083430, PMID 26400368, PMID 27672117, PMID 28039616, PMID 28526798, PMID 28657784, PMID 28883090, PMID 28993537, PMID 29150411, PMID 29445374, PMID 30176872, PMID 30369044, PMID 30729456, PMID 30971229, PMID 31179008, PMID 32160670, PMID 32217654, PMID 33239000, PMID 33463535, PMID 36724330, PMID 37116909, PMID 37159034, PMID 38238788, PMID 38288082, PMID 38509495, PMID 40355288, PMID 41345848, PMID 42166233

NIH funding

2023 (10), 2015 (9), 2019 (6), 2017 (5), 2016 (4), 2018 (4), 2025 (4), 2014 (3), U10HL080413 (3), R01HL097163 (2), 1RC2HL101740-01 (1), 1UM1HL113115-01A1 (1), 1UM1HL119089 (1), 2004 (1), 2009 (1)